Curr Alzheimer Res. 2009 Apr; 6(2): 171–178.
PMCID: PMC2825666

Natural Non-Trasgenic Animal Models for Research in Alzheimer’s Disease


The most common animal models currently used for Alzheimer disease (AD) research are transgenic mice that express a mutant form of human Aβ precursor protein (APP) and/or some of the enzymes implicated in their metabolic processing. However, these transgenic mice carry their own APP and APP-processing enzymes, which may interfere in the production of different amyloid-beta (Aβ) peptides encoded by the human transgenes. Additionally, the genetic backgrounds of the different transgenic mice are a possible confounding factor with regard to crucial aspects of AD that they may (or may not) reproduce. Thus, although the usefulness of transgenic mice is undisputed, we hypothesized that additional relevant information on the physiopathology of AD could be obtained from other natural non-transgenic models. We have analyzed the chick embryo and the dog, which may be better experimental models because their enzymatic machinery for processing APP is almost identical to that of humans. The chick embryo is extremely easy to access and manipulate. It could be an advantageous natural model in which to study the cell biology and developmental function of APP and a potential assay system for drugs that regulate APP processing. The dog suffers from an age-related syndrome of cognitive dysfunction that naturally reproduces key aspects of AD including Aβ cortical pathology, neuronal degeneration and learning and memory disabilities. However, dense core neuritic plaques and neurofibrillary tangles have not been consistently demonstrated in the dog. Thus, these species may be natural models with which to study the biology of AD, and could also serve as assay systems for Aβ-targeted drugs or new therapeutic strategies against this devastating disease.

Keywords: Chick embryo, dog, dolphin, rabbit, rat, APP, Aβ.


The ethics of scientific research obliges to reduce the use of laboratory animals to the minimum possible. Nevertheless, studies in animal models are still necessary to understand the mechanisms of many human diseases and to try new therapeutic strategies. In any case, experiments with animals must always be approved by ethical committees and to enforce general and local normatives (see for example European and Spanish legislations on animal handling 86/609/EU and Real Decreto 1201/2005, respectively).

Rodents in general, and the rat and the mouse in particular, are the animals most frequently used as experimental model organisms for a great variety of human diseases. The short reproductive cycle of these small mammals (21 days of gestation), their high birth rate, and their small size make them relatively easy to maintain and manage. Recent developments in genetic engineering and biotechnology have led to the production of a diverse selection of transgenic animals, mainly mice. These transgenic animals (bearing an exogenous gene, usually from human origin), together with other agenics or knockouts (in which a particular gene has been blocked or eliminated) have been very useful in studying the presumptive roles and mechanisms involving the proteins coded by the transgene or the knockout gene of interest. Translational research has brought particular these technologies to the field of clinical investigation, with the production of inbred animal lines that serve as models for human diseases. Numerous knockout and transgenic animal models have been developed to explore particular aspects of Alzheimer’s disease.

Suppression of genes that encode proteins involved in Alzheimer’s, such as APP, apolipoprotein E (ApoE), β-secretase, or presenilins, has helped us to anticipate the effects of presumptive new molecules designed to regulate these proteins. For example, presenilin knockout mice develop striking neurodegeneration of the cerebral cortex and worsening impairments of memory and synaptic function with increasing age, which call for caution in the therapeutic use of γ-secretase inhibitors [1]. In contrast, β-secretase knockout mice are perfectly viable [2]. The absence of lethal phenotypes for β-secretase knockouts, which cannot generate Aβ peptide, feeds the hope of success for therapeutic strategies based on the use of β-secretase inhibitors or aimed directly at the blockade or elimination of Aβ peptide. Nevertheless, APP knockout mice present overt neurological deficiencies which can be reverted if the endogenous APP locus is replaced by a gene-targeted allele (knock-in mice) that exclusively express the secreted APP ectodomain [3, 4]. In addition, functional redundancy between APP and other APP-like proteins has been reported [5]. The development of transgenic mice lines with mutated human APP genes has been particularly enlightening, since these animals develop Aβ deposits in their brains and reproduce some of the neurological symptoms of AD. However, most of these species lack essential features of AD despite the increasingly complex genotypes that are being engineered to approach a more complete disease phenotype [6-14]. The heterogeneity of different transgenics should be considered a possible confounding factor that seeds doubts when observations made in humans must be interpreted in the light of results obtained in these models. Uncertainty is also unavoidable when the efficacy of new AD therapies must be forecasted from trials in transgenic mice.

Thus, although the usefulness of transgenic mice is undisputed, we hypothesized that additional relevant information regarding the pathological mechanisms of AD could be obtained from natural non-transgenic models. In the following pages we will refer to some of the results obtained in our laboratory that led us to propose new wild type animal models for the analysis of relevant aspects of AD. We have designed and produced highly specific and sensitive antibodies against the two major isoforms of the Aβ amyloid to aid in this research, and are currently exploring the use of these Aβ immunogens in the search for premorbid biomarkers and immunotherapeutic strategies.


The rat is the most frequently utilized experimental animal in neuroscience, although with regard to AD the use of transgenic mice has been increasing. Nevertheless, an enormous amount of work has been produced in the rat, and important advances in the understanding of APP processing— including the studies central to the discovery of neprilysin [15] and insulin degrading enzyme (IDE) [16] as the main proteases implicated in Aβ degradation— have been obtained from experiments conducted in rats. The rat has also been used to study the effects of induced cortical Aβ accumulation on the cholinergic, noradrenergic, and serotonergic systems [17], as well as the influence of diet and age on the effects of intracerebral beta-amyloid injection [18]. However, it should be emphasized that the primary structures of the Aβ peptide in rats (and mice) differ from their human counterpart at three amino acid residues, and that the complete Aβ-peptide profile produced by the processing of APP in these rodents’ also reveals major differences compared to that of humans [19].

In our laboratory, the rat was chosen to study the kinetics of the expression of the different APP isoforms in response to axotomy [20]. We found increased levels of APP 695, 714, 751, and 770 mRNAs after facial or hypoglossal nerve axotomy of the parent ipsilateral motor neurons. The increase was gradual, reaching maximal values 7 days after axotomy, and returning to normal values by 60 days after the lesion. Increased APP immunostaining was also detected in the chromatolytic motor neurons, but not in the reactive astrocytes surrounding axotomized neurons. These results suggested a possible neuroprotective role for APP that could also be involved in a variety of cell processes that remain poorly understood [21-23]. In particular, APP has been implicated in neurotrophic, synaptogenic, and growth-promoting mechanisms which led us to investigate the expression of this protein during the rat embryogenesis [24]. Using oligonucleotides recognizing each of the four major APP (APP-695, APP-714, APP-751, and APP-770) mRNAs, we found that each APP displays a specific temporal and spatial expression pattern. The prototype isoform APP-695 appears early in embryogenesis within cells actively implicated in morphogenetic events, such as the mesodermal cells that invaginate at the level of the primitive streak, and is later restricted to the neurectodermal derivatives (neural tube, neural crest, and neurogenic placode). By contrast, expression of the longest isoform, APP-770, occurs later and is restricted to mesodermal and endodermal derivatives. The isoforms of 714 and 751 amino acids are expressed still later in the course of prenatal development, and appear to be distributed ubiquitously.

Another wild type rodent used for research in AD is the guinea pig [25]. Beta-amyloid peptide sequence expressed by guinea pigs is identical to the human sequence, and appears to represent a more physiological model with which to examine in vivo the long-term effects of experimental manipulations on APP processing. Additionally, APP processing in guinea pig primary neuronal cultures is demonstrably similar to analogous cultures of human origin [25]. However, the use of these animals is limited because they do not develop the pathological features of the disease (senile plaques and neurofibrillary tangles) and there are not well-established behavioral tests for this species.


As in guinea pigs, the rabbit Aβ peptide sequence is identical to human [26] and does not present AD pathology spontaneously. However, when copper is added to the diet of cholesterol-fed rabbits, they develop cortical amyloid deposits and up to twelve other pathological markers seen in AD, including retardation of the ability to learn a difficult task [27]. This finding suggests that copper (but apparently not other heavy metals like aluminum or zinc) may influence the progression of Alzheimer's disease by reducing clearance of Aβ from the brain [28, 29]. This finding also emphasized the usefulness of the rabbit model, whose validity is being extended even to treatment modalities [30-32].


Our studies regarding the prenatal expression of different APPs in the rat embryo [24] were coincident in time with the publication of reports on the lack of substantial phenotypic differences in APP knockout mice [5]. This led us to explore the chick embryo as a possible model for the investigation of presumptive APP functions during prenatal development. The chick embryo is readily available and easy to work with, and our laboratory has extensive experience with this model. Before engaging in experiments on the functional blocking of APP, we first needed to know the sequence of the APP gene in the chicken. We isolated the total RNA from the chick embryo and cloned the cDNA [33]. We found two of the major APP isoforms, APP-751, which contains the KPI domain, and APP-695. The APP-770 isoform, which is the longest isoform and contains the OX-2 domain, was absent or minimally expressed. Interestingly, the chick and human gene sequences are almost identical, with 93% amino acid identity and 96% similarity. The KPI domain of APP-751 has 52 identical residues out of 56 (93% identity), and three of the four different residues belong to the same group of amino acids (98% similarity). The 40–42 amino acid residues of the Aβ domain are identical, as are the last 101 C-terminal amino acids of the APP sequence (corresponding to the Aβ, transmembrane and intracytoplasmic domains). We also established through whole-mount in situ hybridization histochemistry and immunohistochemistry1 that chicken APP expression parallels mammalian APP expression both temporally and topographically [32]. After the 3rd day of embryonic development, APP-695 mRNA expression levels were much higher than APP-751 expression levels in the neuroectodermal derivatives, including the neural tube; the sensory, autonomic and cranial ganglia; the retina; and the otic vesicle. Furthermore, the chick embryo expresses the genes that encode the main proteases implicated in the production of beta amyloid protein, including BACE-1, BACE-2, presenilin-1, presenilin-2, and nicastrin; Aβ1-42 is the major Aβ peptide produced during chick embryogenesis [33]. Neprilysin, the main Aβ-degrading enzyme, and ADAM-17, a protease implicated in the non-amyloidogenic processing of APP, are also expressed in chick embryos. Thus, we propose the chick embryo as a suitable natural model in which to study the cell biology and developmental function of beta-amyloid precursor protein, and a potential assay system for drugs that regulate beta-amyloid precursor protein processing. But do chicks suffer any Alzheimer-like pathology? We have explored whether relatively aged chickens might develop brain amyloid pathology, and have obtained negative results. However, our access has been limited to the brains of chicken up to 10 years old; these individuals appear to be too young to develop amyloid deposits, since the chicken lifespan reaches approximately 30 years [34]. In fact, the brains of 10-year-old chickens do not appear to differ from the brains of chickens between 2 and 14 months old.


The dog has been pointed out as an especially appropriate model for the study of human brain aging and neurodegenerative diseases. The numerous domestic dog breeds exhibit greater diversity in body size than any other terrestrial vertebrate, and geneticists are taking advantage of this diversity to investigate the genetic basis of size and its relationship to lifespan [35-37]. Canines have evolved phylogenetically in close proximity to humans, making them unusually skilled at reading human social and communicative behavior— even more so than our nearest primate relatives [38, 39]. Provided that ethical normative is enforced, individuals of every age are available for study among the immense population of pet dogs. Canine neurology, including behavioral medicine, is state of the art among veterinary clinical sciences, and access to longitudinal records is already possible in many cases [40, 41]. Dogs are frequently used for the preclinical development of a wide variety of drugs (see for example [42, 43]). Regarding AD, almost every current treatment strategy has been tried out in the dog, from cholinergic agonists to antioxidant and mitochondrial enzymatic cofactors [44-49]. Increasing interest in this model is based on the fact that the dog may naturally develop an age-related cognitive dysfunction that reproduces several aspects of AD [47, 50-53]. Thus, numerous studies with dog cohorts that were submitted to several behavioral paradigms have revealed subsets of aged dogs that had learning and memory impairments [46, 54-57]. This cognitive damage correlated with the extent of Aβ deposits in the cerebral cortex [58-60]. Interestingly, a similar correlation has been reported in domestic pet dogs, based on cognitive status evaluated from questionnaires that were answered by their caregivers [61-63]. Most of these tests for evaluation of the cognitive status assess four main behavioural categories: disorientation (on daily walks or at home), interaction with owners (lost of interest in greeting or playing; lost of response to incitation), sleep/awake cycle (wander and/or bark during night) and lost of the house training habits. It has been reported that 28% of 11-12 year old dogs present impairments in one or more of these categories, of which 10% have impairments in two or more categories and are considered severely impaired. Among 15-16 year old dogs, 68% have impairment in one or more category, of which 35% have impairments in two or more categories [64, 65].

Histopathological studies on this putative canine model of AD showed that the earliest and more consistently affected areas were in the prefrontal cortex, including the gyrus proreus and the hippocampus [59, 66, 67]. Deposition of Aβ in the dog appears to progress from deep to superficial cortical layers, and from diffuse patches to denser and better-delimited plaques [68]. However, dense core neuritic plaques and neurofibrillary tangles have not been consistently demonstrated in the dog [69-72]. Aβ deposits do not appear in every aged dog, as might be expected if they were merely a consequence of normal aging (Fig. 1A1A--CC). Instead, as occurs in humans, exogenous and/or genetic factors may determine the susceptibility of individual dogs toward developing amyloid pathology at a given age [73, 74]. Nevertheless, in a recent study we have found Aβ angiopathy and a moderate to heavy Aβ burden in two aged dogs, although they have no apparent cognitive symptoms. This finding is reminiscent of similar reports of extensive Aβ deposits in human brains that had not been diagnosed with dementia (reviewed by [75]). It poses the possibility that, as occurs in AD, the development of neuropathological lesions may precede apparent clinical symptoms by a long period of time in the dog. The availability of biomarkers and more refined neuropsychological tests in veterinary clinics may enable the definition of a canine model for mild cognitive impairment in the near future.

Fig (1)
(1A-G). The canine model of Alzheimer’s disease.

We have recently found that the canine is also a suitable AD model from the molecular point of view, because APP and most of the enzymatic machinery for its processing bear extensive homology between dogs and humans (GenBank accessions AY926579 for APP770, AY926580 for APP751, AY926581 for APP714, AY926582 for APP695, AY926587 for ApoE, AY926590 for presenilin-1, AY926591 for presenilin-2, AY926592 for BACE, AY926593 for ADAM-10, AY926594 for ADAM-17 and AY926595 for pleckstrin). In particular, the amino acid sequence of Aβ1-42 is identical in dogs and humans, whereas in rats and mice it differs from the human sequence by three amino acids [26]. Furthermore, the profile of the various shorter Aβ peptides found by mass spectrometry in the canine LCR is almost identical to that found in humans, and both present substantial differences when compared to rats and mice [19]. Thus, the study of both APP and Aβ peptide processing in the dog could help us to understand their biological function and relevance to AD, contributing results more reliably translatable to humans than those obtained using transgenic mice. The dog has also been used in immunotherapeutic assays against fibrillar Aβ, and to confirm observational data in humans that combining an antioxidant-enriched diet and behavioral enrichment (including social, physical, and cognitive components) can lead to substantial improvements in cognition and reduced brain pathology [47, 76].

However, a pitfall for a more extended use of the dog is the dearth of neuroanatomical data regarding the organization, normal aging process, and response to pathological aging of the main neurotransmitter systems implicated in AD. We have begun to study this issue and have made a number of relevant findings. The cytoarchitectural characteristics of the basal forebrain cholinergic neurons in the dog are similar to those of humans, as are several relevant phenotypic characteristics of these neurons, including their expression of NOS, calbindin D-28K, and p75NTR nerve growth factor receptor (Fig. 1D1D--GG) [77]. As has been found in AD brains, the number of A6-A7 noradrenergic neurons in the dog shows a negative correlation with the extension of cortical Aβ deposits as measured in the gyrus proreus [78].

The investigation of brain aging in the dog also deserves attention from a veterinary point of view. As in the case of human medical technologies, improvements in veterinary medicine and husbandry have contributed to lengthening the lifespan of our domestic animals, with the unwanted side effect of a greater incidence of age-related neurodegenerative diseases [44]. The modern society requires more attention to the welfare of pet animals, increasingly considered as actual “family members”, and there is a growing demand for attention and treatment of these pet dogs’ age related diseases.


Primates, like dogs, are among the few animal species demonstrating age-dependent brain pathologies resembling AD [79-82]. An important advantage of several primate models, but not all [80], is that they show AD-like tau-pathology accounting for a more complete disease model. More over, some of these species have relatively short life span as for example the mouse lemur (Microcebus murinus) which is considered to be elderly over 5 years of age. Interestingly, among elderly mouse lemurs approximately 20% develop massive brain atrophy, abundant amyloid plaques, cytoskeletal Tau pathology and loss of cholinergic neurons [83]. Furthermore, recently it has been documented the first case of tauopathy with paired helical filaments, ultrastructurally indistinguishable from those seen in Alzheimer's disease, in an aged chimpanzee (Pan troglodytes) [84]. Pathologic forms of tau were histologically identified in neuronal somata, neuropil threads, and plaque-like clusters of neurites throughout the neocortex of this animal. Nevertheless, accumulation of the abnormally phosphorylated tau protein in the brains of animals has been less study than the formation of Aβ deposits. Age-related neurofibrillary changes were described in sheep and goat in the absence of Aβ [85-87] and in wolverine (Gulo gulo) [88], polar bear [89] and dog [72] in the presence of Aβ. Thus, non-primate species develop age-related cytoskeletal abnormalities similar to those occurring in humans. However to define an operative model from these species is hampered by which appear to be species specific variations in the process of phosphorylation and cleavage of tau protein. This, together with their phylogenetic proximity to humans, would make primates ideal experimental models (for example, leading studies in immunotherapy are currently being carried out in these species) [90, 91]. However, their use is extremely limited for most laboratories because of high price, restricted availability, maintenance requirements, and ethical considerations.

Other animals that may suffer brain pathology resembling AD are cetaceans. Some cetacean species like dolphins have extended life spans, could be accessible in determined circumstances, and might be useful models to analyze some aspects of the disease. We recently hypothesized that the coastal beaching of these animals could be related to cognitive impairments of the aged individuals (occasionally followed by herds of younger specimens) that might present with Aβ deposits or other AD like neuropathological features. In tissue samples from stranded dolphins, we have found extensive Congo red positive Aβ-immunolabeled deposits throughout the brain, including the cerebellum and the medulla oblongata where such deposits have only been reported in the more severe AD cases2. In addition, we have found high amino acidic homology between the APP, BACE, presenilin-1, and presenilin-2 in various dolphin species and their corresponding human counterpart (GeneBank entries: AY926583, AY926588, AY926589, AY926584, AY926586 and AY926585); in particular, the Aβ1-42 peptide in the three dolphin species that have been studied so far (Grampus griseus, Stenella coeruleoalba and Tursiops truncatus) was 100% identical to the human peptide.


There are a variety of species that can serve as experimental models for AD research. In addition to numerous transgenic mouse lines, which have proven to be powerful tools to aid in understanding various aspects of the disease, there are other species that can serve as ‘natural’ wild-type models to shed light on different psychopathological mechanisms or even to try new therapeutic strategies. Among these natural models we emphasize the chick embryo to assay molecules that act on APP metabolism, and the canine model specifically to study the first phase of the disease and to test new therapies. Dogs have a relatively long lifespan (12-20 years depending on the breed), share our environment, and their behavior and clinical state are easier to explore than those of other species. Furthermore, canine APP is identical (98%) to the human counterpart, and dogs are the most accessible among the few animal species demonstrating age-dependent brain pathology and clinical correlates resembling AD.


The works included in this review have been financed by the Spanish Ministerio de Ciencia y Tecnología and FEDER (project #. SAF2003-08444; SAF2003-08444-C02-02; SAF2006-13332), by the Xunta de Galicia (project # PGIDIT04PXIC26105PN), by the Diputación General de Aragón (project # PM040) and FIS (PI04/0620).


1Domínguez L, Garza V, Lacosta AM, Sorribas V and Sarasa M. Developmental spatiotemporal expression of Alzheimer APP isoforms in the chick embryo. Int J Dev Biol 45(S1): S73-S74 (2001).

2Sarasa M and Gallego MC. Alzheimer-like neurodegeneration as a probable cause of cetacean stranding. 5th Forum of European Neuroscience. Viena, 8-13th July (2006).


The authors declare no actual or potential conflicts of interest. Araclon Biotech S.L. is a start-up biotechnology company aiming to develop biomarkers and therapeutics for Alzheimer's disease and other disorders. Manuel Sarasa is the scientific founder and program director for Araclon Biotech S.L., and he owns shares in the company. Pedro Pesini is head of laboratory in Araclon Biotech S.L.


1. Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004;42:23–36. [PubMed]
2. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci. 2001;4:231–2. [PubMed]
3. Muller U, Cristina N, Li ZW, Wolfer DP, Lipp HP, Rulicke T, et al. Behavioral and anatomical deficits in mice homozygous for a modified beta-amyloid precursor protein gene. Cell. 1994;79:755–65. [PubMed]
4. Ring S, Weyer SW, Kilian SB, Waldron E, Pietrzik CU, Filippov MA, et al. The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice. J Neurosci. 2007;27:7817–26. [PubMed]
5. Heber S, Herms J, Gajic V, Hainfellner J, Aguzzi A, Rulicke T, et al. Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. J Neurosci. 2000;20:7951–63. [PubMed]
6. Gómez-Isla T, Irizarry MC. Alzheimer's disease and transgenic mouse models. In: Boller F, Kappa S, editors. Handbook of neuropsychology. Amsterdam: Elsevier; 2001. pp. 23–37.
7. Mudher A, Lovestone S. Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci. 2002;25:22–6. [PubMed]
8. Price DL, Sisodia SS. Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci. 1998;21:479–505. [PubMed]
9. Lannfelt L, Folkesson R, Mohammed AH, Winblad B, Hellgren D, Duff K, et al. Alzheimer's disease molecular genetics and transgenic animal models. Behav Brain Res. 1993;57:207–13. [PubMed]
10. Price DL, Sisodia SS. Cellular and molecular biology of Alzheimer's disease and animal models. Annu Rev Med. 1994;45:435–46. [PubMed]
11. Bayer TA, Wirths O. Review on the APP/PS1KI mouse model: intraneuronal Abeta accumulation triggers axonopathy, neuron loss and working memory impairment. Genes Brain Behav. 2008;7(1):6–11. [PubMed]
12. Higgins GA, Jacobsen H. Transgenic mouse models of Alzheimer's disease: phenotype and application. Behav Pharmacol. 2003;14:419–38. [PubMed]
13. Dodart JC, Mathis C, Bales KR, Paul SM. Does my mouse have Alzheimer's disease? Genes Brain Behav. 2002;1:142–55. [PubMed]
14. van Dooren T, Dewachter I, Borghgraef P, van Leuven F. Transgenic mouse models for APP processing and Alzheimer's disease: early and late defects. Subcell Biochem. 2005;38:45–63. [PubMed]
15. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med. 2000;6:143–50. [PubMed]
16. Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, et al. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci. 2000;20:1657–65. [PubMed]
17. Gonzalo-Ruiz A, Gonzalez I, Sanz-Anquela JM. Effects of beta-amyloid protein on serotoninergic, noradrenergic, and cholinergic markers in neurons of the pontomesencephalic tegmentum in the rat. J Chem Neuroanat. 2003;26:153–69. [PubMed]
18. Gonzalo-Ruiz A, Sanz JM, Arevalo J, Geula C, Gonzalo P. Amyloid beta peptide-induced cholinergic fibres loss in the cerebral cortex of the rat is modified by diet high in lipids and by age. J Chem Neuroanat. 2005;29:31–48. [PubMed]
19. Du P, Wood KM, Rosner MH, Cunningham D, Tate B, Geoghegan KF. Dominance of amyloid precursor protein sequence over host cell secretases in determining beta-amyloid profiles studies of interspecies variation and drug action by internally standardized immunoprecipitation/mass spectrometry. J Pharmacol Exp Ther. 2007;320:1144–52. [PubMed]
20. Sola C, Garcia-Ladona FJ, Sarasa M, Mengod G, Probst A, Palacios G, et al. Beta APP gene expression is increased in the rat brain after motor neuron axotomy. Eur J Neurosci. 1993;5:795–808. [PubMed]
21. Wang P, Yang G, Mosier DR, Chang P, Zaidi T, Gong YD, et al. Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-Like protein 2. J Neurosci. 2005;25:1219–25. [PubMed]
22. Anliker B, Muller U. The functions of mammalian amyloid precursor protein and related amyloid precursor-like proteins. Neurodegener Dis. 2006;3:239–46. [PubMed]
23. Koo EH. The beta-amyloid precursor protein (APP) and Alzheimer's disease: does the tail wag the dog? Traffic. 2002;3:763–70. [PubMed]
24. Sarasa M, Sorribas V, Terradoa1 J, Climent S, Palacios JM, Mengod G. Alzheimer beta-amyloid precursor proteins display specific patterns of expression during embryogenesis. Mech Dev. 2000;94:233–6. [PubMed]
25. Beck M, Bigl V, Rossner S. Guinea pigs as a nontransgenic model for APP processing in vitro and in vivo. Neurochem Res. 2003;28:637–44. [PubMed]
26. Johnstone EM, Chaney MO, Norris FH, Pascual R, Little SP. Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis. Brain Res Mol Brain Res. 1991;10:299–305. [PubMed]
27. Sparks DL, Schreurs BG. Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc Natl Acad Sci USA. 2003;100:11065–9. [PMC free article] [PubMed]
28. Sparks DL. Cholesterol metabolism and brain amyloidosis: evidence for a role of copper in the clearance of Abeta through the liver. Curr Alzheimer Res. 2007;4:165–9. [PubMed]
29. Sparks DL, Friedland R, Petanceska S, Schreurs BG, Shi J, Perry G, et al. Trace copper levels in the drinking water, but not zinc or aluminum influence CNS Alzheimer-like pathology. J Nutr Health Aging. 2006;10:247–54. [PMC free article] [PubMed]
30. Ghribi O, Golovko MY, Larsen B, Schrag M, Murphy EJ. Deposition of iron and beta-amyloid plaques is associated with cortical cellular damage in rabbits fed with long-term cholesterol-enriched diets. J Neurochem. 2006;99:438–49. [PubMed]
31. Ghribi O, Larsen B, Schrag M, Herman MM. High cholesterol content in neurons increases BACE, beta-amyloid, and phosphorylated tau levels in rabbit hippocampus. Exp Neurol. 2006;200:460–7. [PubMed]
32. Woodruff-Pak DS, Agelan A, Del Valle L. A rabbit model of Alzheimer's disease: valid at neuropathological, cognitive, and therapeutic levels. J Alzheimers Dis. 2007;11:371–83. [PubMed]
33. Carrodeguas JA, Rodolosse A, Garza MV, Sanz-Clemente A, Perez-Pé R, Lacosta AM, et al. The chick embryo appears as a natural model for research in beta-amyloid precursor protein processing. Neuroscience. 2005;134:1285–300. [PubMed]
34. Dani SU. Mechanisms of aging: A survey. In: Dani SU, Hori A, Walter GF, editors. Principles of Neural Aging. Amsterdam: Elsevier; 1997. pp. 5–18.
35. Speakman JR. Body size, energy metabolism and lifespan. J Exp Biol. 2005;208:1717–30. [PubMed]
36. Speakman JR, van Acker A, Harper EJ. Age-related changes in the metabolism and body composition of three dog breeds and their relationship to life expectancy. Aging cell. 2003;2:265–75. [PubMed]
37. Sutter NB, Bustamante CD, Chase K, Gray MM, Zhao K, Zhu L, et al. A single IGF1 allele is a major determinant of small size in dogs. Science. 2007;316:112–5. [PMC free article] [PubMed]
38. Hare B, Brown M, Williamson C, Tomasello M. The domestication of social cognition in dogs. Science. 2002;298:1634–6. [PubMed]
39. Hare B, Tomasello M. Human-like social skills in dogs? Trends Cogn Sci. 2005;9:439–44. [PubMed]
40. Overall KL. Clinical behavioral medicine for small animals. Missouri Mosby: St. Louis; 1997.
41. Pageat P. Patología del comportamiento del perro. 2nd. Barcelona: Pulso; 2000.
42. Hu J, Chen H, Li Y. Development of a gas chromatography-time-of-flight mass spectrometry method for the determination of buagafuran, a promising antianxiety drug in dog blood. J Pharm Biomed Anal. 2008;47:383–7. [PubMed]
43. Cuyckens F, Balcaen LI, De Wolf K, De Samber B, Van Looveren C, Hurkmans R, et al. Use of the bromine isotope ratio in HPLC-ICP-MS and HPLC-ESI-MS analysis of a new drug in development. Anal Bioanal Chem. 2008;390:1717–29. [PubMed]
44. Landsberg G. Therapeutic agents for the treatment of cognitive dysfunction syndrome in senior dogs. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:471–9. [PubMed]
45. Milgram NW, Zicker SC, Head E, Muggenburg BA, Murphey H, Ikeda-Douglas CJ, et al. Dietary enrichment counteracts age-associated cognitive dysfunction in canines. Neurobiol Aging. 2002;23:737–45. [PubMed]
46. Siwak CT, Tapp PD, Head E, Zicker SC, Murphey HL, Muggenburg BA, et al. Chronic antioxidant and mitochondrial cofactor administration improves discrimination learning in aged but not young dogs. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:461–9. [PubMed]
47. Head E. Combining an antioxidant-fortified diet with behavioral enrichment leads to cognitive improvement and reduced brain pathology in aging canines: strategies for healthy aging. Ann N Y Acad Sci. 2007;1114:398–406. [PubMed]
48. Araujo JA, Studzinski CM, Milgram NW. Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:411–22. [PubMed]
49. Siwak CT, Gruet P, Woehrle F, Muggenburg BA, Murphey HL, Milgram NW. Comparison of the effects of adrafinil, propentofylline, and nicergoline on behavior in aged dogs. Am J Vet Res. 2000;61:1410–4. [PubMed]
50. Siwak-Tapp CT, Head E, Muggenburg BA, Milgram NW, Cotman CW. Region specific neuron loss in the aged canine hippocampus is reduced by enrichment. Neurobiol Aging. 2008;29:39–50. [PMC free article] [PubMed]
51. Opii WO, Joshi G, Head E, Milgram NW, Muggenburg BA, Klein JB, et al. Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: Relevance to Alzheimer's disease. Neurobiol Aging. 2008;29:51–70. [PMC free article] [PubMed]
52. Head E, Liu J, Hagen TM, Muggenburg BA, Milgram NW, Ames BN, et al. Oxidative damage increases with age in a canine model of human brain aging. J Neurochem. 2002;82:375–81. [PubMed]
53. Cummings BJ, Head E, Ruehl W, Milgram NW, Cotman CW. The canine as an animal model of human aging and dementia. Neurobiol Aging. 1996;17:259–68. [PubMed]
54. Tapp PD, Siwak CT, Estrada J, Holowachuk D, Milgram NW. Effects of age on measures of complex working memory span in the beagle dog (Canis familiaris) using two versions of a spatial list learning paradigm. Learn Mem. 2003;10:148–60. [PMC free article] [PubMed]
55. Adams B, Chan A, Callahan H, Siwak C, Tapp D, Ikeda-Douglas C, et al. Use of a delayed non-matching to position task to model age-dependent cognitive decline in the dog. Behav Brain Res. 2000;108:47–56. [PubMed]
56. Head E, Mehta R, Hartley J, Kameka M, Cummings BJ, Cotman CW, et al. Spatial learning and memory as a function of age in the dog. Behav Neurosci. 1995;109:851–8. [PubMed]
57. Siwak CT, Tapp PD, Milgram NW. Effect of age and level of cognitive function on spontaneous and exploratory behaviors in the beagle dog. Learn Mem. 2001;8:317–25. [PMC free article] [PubMed]
58. Head E, Callahan H, Muggenburg BA, Cotman CW, Milgram NW. Visual-discrimination learning ability and beta-amyloid accumulation in the dog. Neurobiol Aging. 1998;19:415–25. [PubMed]
59. Head E, McCleary R, Hahn FF, Milgram NW, Cotman CW. Region-specific age at onset of beta-amyloid in dogs. Neurobiol Aging. 2000;21:89–96. [PubMed]
60. Cummings BJ, Head E, Afagh AJ, Milgram NW, Cotman CW. Beta-amyloid accumulation correlates with cognitive dysfunction in the aged canine. Neurobiol Learn Mem. 1996;66:11–23. [PubMed]
61. Colle M-A, Hauw J-J, Crespeau F, Uchihara T, Akiyama H, Checler F, et al. Vascular and parenchymal Abeta deposition in the aging dog: correlation with behavior. Neurobiol Aging. 2000;21:695–704. [PubMed]
62. Pugliese M, Geloso MC, Carrasco JL, Mascort J, Michetti F, Mahy N. Canine cognitive deficit correlates with diffuse plaque maturation and S100beta (-) astrocytosis but not with insulin cerebrospinal fluid level. Acta Neuropathol (Berl) 2006;111:519–28. [PubMed]
63. Rofina JE, van Ederen AM, Toussaint MJ, Secreve M, van der Spek A, van der Meer I, et al. Cognitive disturbances in old dogs suffering from the canine counterpart of Alzheimer's disease. Brain Res. 2006;1069:216–26. [PubMed]
64. Neilson JC, Hart BL, Cliff KD, Ruehl WW. Prevalence of behavioral changes associated with age-related cognitive impairment in dogs. J Am Vet Med Assoc. 2001;218:1787–91. [PubMed]
65. Bain MJ, Hart BL, Cliff KD, Ruehl WW. Predicting behavioral changes associated with age-related cognitive impairment in dogs. J Am Vet Med Assoc. 2001;218:1792–5. [PubMed]
66. Hou Y, White RG, Bobik M, Marks JS, Russell MJ. Distribution of beta-amyloid in the canine brain. Neuroreport. 1997;8:1009–12. [PubMed]
67. Yoshino T, Uchida K, Tateyama S, Yamaguchi I, Nakayama H, Goto. N. A retrospective study of canine senile plaques and cerebral amyloid angiopathy. Vet Pathol. 1996;33:230–4. [PubMed]
68. Satou T, Cummings BJ, Head E, Nielson KA, Hahn FF, Milgram NW, et al. The progression of beta-amyloid deposition in the frontal cortex of the aged canine. Brain Res. 1997;774:35–43. [PubMed]
69. Papaioannou N, Tooten PC, van Ederen AM, Bohl JR, Rofina J, Tsangaris T, et al. Immunohistochemical investigation of the brain of aged dogs. I. Detection of neurofibrillary tangles and of 4-hydroxynonenal protein, an oxidative damage product, in senile plaques. Amyloid. 2001;8:11–21. [PubMed]
70. Wisniewski T, Lalowski M, Bobik M, Russell M, Strosznajder J, Frangione B. Amyloid beta 1-42 deposits do not lead to Alzheimer's neuritic plaques in aged dogs. Biochem J. 1996;313(Pt 2):575–80. [PMC free article] [PubMed]
71. Pugliese M, Mascort J, Mahy N, Ferrer I. Diffuse beta-amyloid plaques and hyperphosphorylated tau are unrelated processes in aged dogs with behavioral deficits. Acta Neuropathol (Berl) 2006;112:175–83. [PubMed]
72. Wegiel J, Wisniewski HM, Soltysiak Z. Region- and cell-type-specific pattern of tau phosphorylation in dog brain. Brain Res. 1998;802:259–66. [PubMed]
73. Wegiel J, Wisniewski HM, Dziewiatkowski J, Tarnawski M, Dziewiatkowska A, Morys J, et al. Subpopulation of dogs with severe brain parenchymal beta amyloidosis distinguished with cluster analysis. Brain Res. 1996;728:20–6. [PubMed]
74. Russell MJ, White R, Patel E, Markesbery WR, Watson CR, Geddes JW. Familial influence on plaque formation in the beagle brain. Neuroreport. 1992;3:1093–6. [PubMed]
75. Swerdlow RH. Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging? Neurobiol Aging. 2007;28:1465–80. [PubMed]
76. Head E, Barrett EG, Murphy MP, Das P, Nistor M, Sarsoza F, et al. Immunization with fibrillar Abeta(1-42) in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Abeta. Vaccine. 2006;24:2824–34. [PubMed]
77. Menéndez L, Insua D, Rois JL, Santamarina G, Suárez ML, Pesini P. The immunohistochemical localization of neuronal nitric oxide synthase in the basal forebrain of the dog. J Chem Neuroanat. 2006;31:200–9. [PubMed]
78. Insua D, Suárez M-L, Santamarina G, Sarasa M, Pesini P. Dogs with canine counterpart of Alzheimer's disease lose noradrenergic neurons. Neurobiol Aging. 2008 In press. [PubMed]
79. Martin LJ, Pardo CA, Cork LC, Price DL. Synaptic pathology and glial responses to neuronal injury precede the formation of senile plaques and amyloid deposits in the aging cerebral cortex. Am J Pathol. 1994;145:1358–81. [PMC free article] [PubMed]
80. Lemere CA, Oh J, Stanish HA, Peng Y, Pepivani I, Fagan AM, et al. Cerebral amyloid-Beta protein accumulation with aging in cotton-top tamarins: a model of early Alzheimer's disease? Rejuvenation Res. 2008;11:321–32. [PubMed]
81. Gearing M, Tigges J, Mori H, Mirra SS, et al. beta-Amyloid (A beta) deposition in the brains of aged orangutans. Neurobiol Aging. 1997;18:139–46. [PubMed]
82. Schultz C, Hubbard GB, Rub U, Braak E, Braak H. Age-related progression of tau pathology in brains of baboons. Neurobiol Aging. 2000;21:905–12. [PubMed]
83. Bons N, Rieger F, Prudhomme D, Fisher A, Krause KH. Microcebus murinus: a useful primate model for human cerebral aging and Alzheimer's disease? Genes Brain Behav. 2006;5:120–130. [PubMed]
84. Rosen RF, Farberg AS, Gearing M, Dooyema J, Long PM, Anderson DC, et al. Tauopathy with paired helical filaments in an aged chimpanzee. J Comp Neurol. 2008;509:259–270. [PMC free article] [PubMed]
85. Braak H, Braak E, Strothjohann M. Abnormally phosphorylated tau protein related to the formation of neurofibrillary tangles and neuropil threads in the cerebral cortex of sheep and goat. Neurosci Lett. 1994;171:1–4. [PubMed]
86. Nelson PT, Greenberg SG, Saper CB. Neurofibrillary tangles in the cerebral cortex of sheep. Neurosci Lett. 1994;170:187–90. [PubMed]
87. Nelson PT, Saper CB. Ultrastructure of neurofibrillary tangles in the cerebral cortex of sheep. Neurobiol Aging. 1995;16:315–23. [PubMed]
88. Roertgen KE, Parisi JE, Clark HB, Barnes DL, O'Brien TD, Johnson KH. A beta-associated cerebral angiopathy and senile plaques with neurofibrillary tangles and cerebral hemorrhage in an aged wolverine (Gulo gulo) Neurobiol Aging. 1996;17:243–7. [PubMed]
89. Cork LC, Powers RE, Selkoe DJ, Davies P, Geyer JJ, Price DL. Neurofibrillary tangles and senile plaques in aged bears. J Neuropathol Exp Neurol. 1988;47:629–41. [PubMed]
90. Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, et al. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol. 2004;165:283–97. [PMC free article] [PubMed]
91. Gandy S, DeMattos RB, Lemere CA, Heppner FL, Leverone J, Aguzzi A, et al. Alzheimer's Abeta vaccination of rhesus monkeys (Macaca mulatta) Mech Ageing Dev. 2004;125:149–51. [PubMed]
PubReader format: click here to try


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem chemical compound records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records. Multiple substance records may contribute to the PubChem compound record.
  • Gene (nucleotide)
    Gene (nucleotide)
    Records in Gene identified from shared sequence and PMC links.
  • MedGen
    Related information in MedGen
  • Nucleotide
    Primary database (GenBank) nucleotide records reported in the current articles as well as Reference Sequences (RefSeqs) that include the articles as references.
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...